Secondary Patenting Of Branded Pharmaceuticals: A Case Study Of How Patents On Two HIV Drugs Could Be Extended For Decades
- 1 October 2012
- journal article
- Published by Health Affairs Publishing, LLC in Health Affairs
- Vol. 31 (10) , 2286-2294
Abstract
Pharmaceutical manufacturers rely on patents to protect their intellectual property and often seek to extend market exclusivity for their products to maximize their return on investment. One method is by obtaining patents on features other than the original active drug ingredient, including secondary patents on alternate formulations of the drug or on methods of administration. This article examines how secondary patents can extend market exclusivity and thus delay generic competition, using as an example two key antiretroviral drugs for the management of HIV: ritonavir (Norvir) and lopinavir/ritonavir (Kaletra). We identified 108 patents, which together could delay generic competition until at least 2028—twelve years after the expiration of the patents on the drugs’ base compounds and thirty-nine years after the first patents on ritonavir were filed. Some of the secondary patents that were reviewed were found to be of questionable inventiveness. We argue that increased transparency for existing patents, stricter patentability standards, and increased opportunities to challenge patent applications and patents could reduce inappropriate market exclusivity extensions on brand-name drugs and open the door to lower-cost generics.Keywords
This publication has 17 references indexed in Scilit:
- State Generic Substitution Laws Can Lower Drug Outlays Under MedicaidHealth Affairs, 2010
- The strategy of enantiomer patents of drugsDrug Discovery Today, 2010
- Basic of US patents and the patent systemThe AAPS Journal, 2007
- Prescription Drug Cost SharingJAMA, 2007
- Medical-Process Patents — Monopolizing the Delivery of Health CareNew England Journal of Medicine, 2006
- Extensions Of Intellectual Property Rights And Delayed Adoption Of Generic Drugs: Effects On Medicaid SpendingHealth Affairs, 2006
- The Implications of ChoiceArchives of internal medicine (1960), 2006
- Evergreening: there's life in the old drug yetBJU International, 2005
- Adverse Events Associated With Prescription Drug Cost-Sharing Among Poor and Elderly PersonsJAMA, 2001
- Qualitative Analysis as a Public Event: The Documentation of Category Development ProceduresAmerican Educational Research Journal, 1992